Skip to content
Health and Human Services (HHS) Secretary Xavier Becerra is reportedly open to the idea of using the “march-in” provision of the Bayh-Dole Act to […]
HHS says march-in rights for drug price controls ‘not off the table’ Read More »
Vir Biotechnology Inc. has won a multi-year agreement with the U.S. government to support pandemic preparedness for influenza and other infectious disease threats, the
Vir Biotechnology gets government funding to address flu and future pandemics Read More »
After two years of virtual programming, the Congressional Black Caucus Foundation’s Annual Legislative Conference (ALC) was held in person from September 28 through October
BIO addresses clinical trial diversity at CBC Annual Legislative Conference event Read More »
U.S. investment in sensitive, cutting-edge research abroad would be more tightly controlled under the proposed National Critical Capabilities Defense Act. The bipartisan legislation would
Bill would limit U.S. investment in foreign research Read More »
A government-wide strategy to scale up “new technologies to manufacture sustainable aviation fuels (SAFs) throughout the U.S. aircraft industry”—something biotech has been working on
Government pushes for 100% SAF in aviation Read More »
The Inflation Reduction Act (IRA) will affect the biotech industry in a variety of ways—especially when it comes to drug development. On the one
What you need to know about the Inflation Reduction Act’s drug provisions Read More »
On Tuesday, the House Ways & Means Committee rejected a Resolution of Inquiry seeking information from the Biden administration on the World Trade Organization
Ways & Means Committee rejects inquiry resolution on COVID IP waiver Read More »
The Senate on Tuesday approved the reauthorization of significant small company seed funding programs: the Small Business Innovation Research and Small Business Technology Transfer
SBIR/STTR reauthorization passes Senate, moves to House Read More »
Amid growing worries about a plan to broaden the WTO’s TRIPS waiver, which strips intellectual property (IP) safeguards for COVID technology, the House Ways
Ways & Means action seeks to highlight plans for an expanded TRIPS waiver Read More »
The federal 340B Drug Pricing Program is starting to get a great deal of attention—for all the wrong reasons. The program was started in
Hospitals and pharmacies profit as 340B drives up patients’ drug costs Read More »
